{
    "clinical_study": {
        "@rank": "62058", 
        "arm_group": [
            {
                "arm_group_label": "Intraventricular tPA", 
                "arm_group_type": "Active Comparator", 
                "description": "Tissue Plasminogen Activator (tPA)\nDose:  1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration:  Intraventricular; via previously placed external ventricular drain"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo\nDose 1 mL sterile saline"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the hypothesis that the administration of intraventricular tPA\n      reduces the rates of cerebral vasospasm and ventriculoperitoneal shunt-dependent\n      hydrocephalus in patients with aneurysmal subarachnoid hemorrhage."
        }, 
        "brief_title": "Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Subarachnoid Hemorrhage", 
            "Cerebral Vasospasm", 
            "Cerebral Aneurysm", 
            "Hydrocephalus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aneurysm", 
                "Hemorrhage", 
                "Hydrocephalus", 
                "Subarachnoid Hemorrhage", 
                "Vasospasm, Intracranial", 
                "Intracranial Aneurysm"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age greater than 18 years old.\n\n          -  SAH due to aneurysm, as determined by CT angiogram or cerebral angiogram.\n\n          -  Modified Fisher (mF) grade 3 or 4 SAH, defined as thick cisternal blood without\n             (grade 3) or with (grade 4) intraventrciular blood.\n\n          -  Exclusion of the aneurysm from the parent circulation by endovascular embolization\n             (Raymond class I or II) within 48 hours of ictus.\n\n          -  Ventriculostomy placement must occur prior to randomization.\n\n          -  Informed consent obtained from the patient or patient's decision maker\n\n        Exclusion Criteria:\n\n          -  Determination by treating physician(s) that no ventriculostomy is needed.\n\n          -  Presence of intrinsic clotting disorders (e.g. due to hepatic failure, nephrotic\n             syndrome, etc).  Subjects whose pharmacologic anticoagulation is reversed, as\n             determined by PT/INR, PTT within our institution's normal range, will be permitted to\n             participate in this study.\n\n          -  Presence of significant anemia, defined as hemoglobin < 8 gm/dL.\n\n          -  Patients who undergo endovascular techniques requiring post-operative dual\n             anti-platelet therapy.\n\n          -  Residual aneurysm sac filling (Raymond class III occlusion).\n\n          -  Aneurysm or vessel perforation during the endovascular procedure.\n\n          -  Presence of craniectomy.\n\n          -  Significant neurologic disability prior to the onset of SAH.\n\n          -  Determination that administration of tPA/placebo cannot be initiated within 72 hours\n             of symptom onset.\n\n          -  Presence of untreated intracranial aneurysms larger than 3mm on CT angiography or\n             cerebral angiogram."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878136", 
            "org_study_id": "13011803"
        }, 
        "intervention": {
            "arm_group_label": "Intraventricular tPA", 
            "description": "Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)", 
            "intervention_name": "Tissue Plasminogen Activator", 
            "intervention_type": "Drug", 
            "other_name": [
                "Activase", 
                "Alteplase"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Plasminogen", 
                "Tissue Plasminogen Activator"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "contact": {
                "email": "Stephan_Munich@Rush.edu", 
                "last_name": "Stephan Munich, MD", 
                "phone": "312-942-1854"
            }, 
            "contact_backup": {
                "email": "Roham_Moftakhar@Rush.edu", 
                "last_name": "Roham Moftakhar, MD", 
                "phone": "3129421854"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60612"
                }, 
                "name": "Rush University Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Stephan Munich, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Andrew Johnson, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nicholas Panos, PharmD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Roham Moftakhar, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage", 
        "overall_contact": {
            "email": "Stephan_Munich@Rush.edu", 
            "last_name": "Stephan Munich, MD", 
            "phone": "3129421854"
        }, 
        "overall_contact_backup": {
            "email": "Carol_MacPherson@Rush.edu", 
            "last_name": "Carol MacPherson", 
            "phone": "3129428614"
        }, 
        "overall_official": [
            {
                "affiliation": "Rush University Medical Center, Department of Neurosurgery", 
                "last_name": "Stephan Munich, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Rush University Medical Center, Department of Neurosurgery", 
                "last_name": "Roham Moftakhar, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The composite primary outcome will consist of the rates of ventriculoperitoneal shunt (VPS) placement, clinically significant vasospasm, and death.  VPS placement serves as surrogate measure of hydrocephalus.  These outcomes will be measured during the patient's hospitalization.", 
            "measure": "Composite Primary Outcome", 
            "safety_issue": "No", 
            "time_frame": "1-60 days after SAH"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878136"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rush University Medical Center", 
            "investigator_full_name": "Stephan Munich", 
            "investigator_title": "Neurosurgery Resident", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "New intracranial hemorrhage will be defined as any new parenchymal or ventricular hemorrhage occurring after the first dose of study drug/placebo.", 
                "measure": "Rate of new intracranial hemorrhage", 
                "safety_issue": "Yes", 
                "time_frame": "1-14 days after SAH"
            }, 
            {
                "description": "The presence of infection will require identification of an offending organism via CSF cultures.", 
                "measure": "Rate of intracranial infection", 
                "safety_issue": "Yes", 
                "time_frame": "1-14 after SAH"
            }
        ], 
        "source": "Rush University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rush University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}